Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UPB-101 · 2 trials · 2 indications
Non-compartmental analysis was used for estimation of PK parameters.
Non-compartmental analysis was used for estimation of PK parameters.
Non-compartmental analysis was used for estimation of PK parameters. AUC = Area under the concentration-time curve
Overall Summary of Treatment-emergent Adverse Events (TEAEs) and Adverse Events (AEs) up to Week 24 (Safety Population)
| Arm | Type | Description |
|---|---|---|
| Treatment Group 1 | EXPERIMENTAL | Single subcutaneous injection of a low dose of UPB-101 (formerly ASP7266) in 8 Japanese participants |
| Treatment Group 2 | EXPERIMENTAL | Single subcutaneous injection of a medium dose of UPB-101 (formerly ASP7266) in 8 Japanese participants |
| Treatment Group 3 | EXPERIMENTAL | Single subcutaneous injection of a high dose of UPB-101 (formerly ASP7266) in 8 Japanese participants |
| Treatment Group 4 | EXPERIMENTAL | Single subcutaneous injection of a high dose of UPB-101 (formerly ASP7266) in 8 Non-Japanese Non-East Asian participants |
| Active substance 1 | EXPERIMENTAL | UPB-101 Cohort 1 |
| Active substance 2 | EXPERIMENTAL | UPB-101 Cohort 2 |
| Active substance 3 | EXPERIMENTAL | UPB-101 Cohort 3 |
| Active Substance 4 | EXPERIMENTAL | UPB-101 Cohort 4 |
| Name | Type | Description |
|---|---|---|
| UPB-101 | DRUG | UPB-101 Subcutaneous injection |
| Placebo | DRUG | Subcutaneous injection |
Main Inclusion Criteria: 1. Male or female, aged ≥18 to ≤40 years at the date of signing informed consent 2. Body mass index (BMI) between 18 and 25 kg/m2 3. For Japanese (treatment groups 1, 2 and 3), participants must be: 1. Born in Japan, holding a Japanese passport, 2. Not living outside...
UPB-101 is an investigational small molecule being studied for the treatment of asthma. It is currently in Phase 1 clinical development, with completed trials evaluating its safety and biologic impact in asthmatics. The drug is not yet approved and remains under investigation.
UPB-101 is being developed by Upstream Bio, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and pharmacodynamics in patients with asthma and in healthy volunteers.
UPB-101 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in asthmatics and one in healthy adults. The drug is investigational and has not been approved by regulatory authorities.
UPB-101 has been studied in two completed Phase 1 trials. NCT05448651 evaluated repeated injections and increasing doses in asthmatics, while NCT05653479 assessed a single injection in healthy Japanese and non-Japanese non-East Asian adults. Both trials were conducted in the United Kingdom.
UPB-101 is the primary name used for this investigational drug. No alternative names have been reported in clinical trial records, and it is not known to be identical to any other approved or investigational medication.